Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26765093 | 0.92 | CYP2C9 (0.60) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL24011155 | 0.89 | CYP2C9 (0.51) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL24011099 | 0.87 | CYP2C9 (0.49) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL24011100 | 0.87 | CYP2C9 (0.49) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL24011564 | 0.86 | NAMPT (0.63) | NAMPTCYP2C9MAPK1CYP3A4ALDH1A1 | |
| SCHEMBL24011315 | 0.84 | NAMPT (0.47) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL26765090 | 0.82 | NAMPT (0.50) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL24011347 | 0.81 | CYP2C9 (0.51) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL24011238 | 0.81 | ALDH1A1 (0.57) | NAMPTCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL24011498 | 0.80 | NAMPT (0.52) | NAMPTCYP2C9MAPK1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115843295-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | NAMPT 1/4885CYP2C9 1551/4885CYP2C19 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.